Medicare Part D coverage · hydroxyurea · RxCUI 2696079
hydroxyurea 100 MG/ML Oral Solution [Xromi]
Per the CMS 2026 Part D formulary file, hydroxyurea 100 MG/ML Oral Solution [Xromi] is covered by 142 Medicare Part D plans (2.8% of enrollable products), averaging Tier 3.7, with prior authorization required on 25% of covering formularies.
- 2.8%
- Plan coverage
- 142
- Plans covering
- T3.7
- Avg tier
- 25%
- Prior auth required
What the CMS Formulary Data Shows for hydroxyurea 100 MG/ML Oral Solution [Xromi]
Per the CMS 2026 Part D formulary file, hydroxyurea 100 MG/ML Oral Solution [Xromi] (RxNorm concept RXCUI 2696079, generic name hydroxyurea) appears on 16 distinct formulary files spanning 142 Medicare Part D plan offerings - 2.8% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 5, with a cross-plan average of Tier 3.7.
Real-world access to hydroxyurea 100 MG/ML Oral Solution [Xromi] depends on utilization management as much as tier placement: 25% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 102,368 Part D beneficiaries filled hydroxyurea 100 MG/ML Oral Solution [Xromi] in 2023, with total plan-and-beneficiary spending of $17,214,624 and an average per-beneficiary annual cost of $168.16. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry hydroxyurea 100 MG/ML Oral Solution [Xromi] today.
Coverage Details
- Formularies covering
- 16
- Plans covering
- 142
- Coverage rate
- 2.8%
- Tier range
- Tier 1 – Tier 5
- Average tier
- Tier 4, Non-Preferred
Restrictions
- Prior authorization required
- 25% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 0% of formularies
2023 Medicare Spending
- Beneficiaries
- 102,368
- Total spending
- $17,214,624
- Avg per beneficiary
- $168.16
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering hydroxyurea 100 MG/ML Oral Solution [Xromi]
100 Medicare Advantage plans with Part D drug coverage include this drug.
| Plan | Insurer | Tier | PA | Premium | States |
|---|---|---|---|---|---|
| SeniorCare Complete (HMO D-SNP) | South Country Health Alliance | T1 | No | $0 | MN |
| AbilityCare (HMO D-SNP) | South Country Health Alliance | T1 | No | $0 | MN |
| Alameda Alliance Wellness (HMO D-SNP) | Alameda Alliance FOR Health | T1 | No | $0 | CA |
| CalOptima Health OneCare Complete (HMO D-SNP) | Orange County Health Authority | T2 | Yes | $0 | CA |
| Troy Medicare (HMO) | Troy Health, Inc. | T4 | No | $0 | NC |
| Troy Medicare for Dual-eligible Beneficiaries (HMO D-SNP) | Troy Health, Inc. | T4 | No | $0 | NC |
| Contra Costa Health Care Plus (HMO D-SNP) | Contra Costa County Medical Service DBA Contra Costa Health | T4 | No | $0 | CA |
| Keystone First VIP Choice (HMO D-SNP) | Vista Health Plan, Inc. | T4 | No | $0 | PA |
| AmeriHealth Caritas VIP Care (HMO D-SNP) | Vista Health Plan, Inc. | T4 | No | $0 | PA |
| First Choice VIP Care (HMO D-SNP) | Select Health OF South Carolina, Inc. | T4 | No | $0 | SC |
| AmeriHealth Caritas VIP Care (HMO D-SNP) | AmeriHealth Caritas VIP Next, Inc. | T4 | No | $0 | DE |
| AmeriHealth Caritas VIP Care Choice (HMO D-SNP) | AmeriHealth Caritas VIP Next, Inc. | T4 | No | $0 | DE |
| AmeriHealth Caritas VIP Care (HMO D-SNP) | Amerihealth Caritas Florida, Inc. | T4 | No | $0 | FL |
| AmeriHealth Caritas VIP Care (HMO D-SNP) | Amerihealth Caritas Louisiana, Inc. | T4 | No | $0 | LA |
| AmeriHealth Caritas VIP Care (HMO D-SNP) | Amerihealth Caritas North Carolina, Inc. | T4 | No | $0 | NC |
| AmeriHealth Caritas VIP Care (HMO D-SNP) | Amerihealth Michigan, Inc. | T4 | No | $0 | MI |
| Health First Rewards H1099-014 (HMO) | Health First Health Plans | T4 | Yes | $0 | FL |
| Health First SunSaver H1099-016 (HMO) | Health First Health Plans | T4 | Yes | $0 | FL |
| Health First Complete Care H1099-023 (HMO) | Health First Health Plans | T4 | Yes | $0 | FL |
| Health First Emerald Plus H1099-024 (HMO) | Health First Health Plans | T4 | Yes | $0 | FL |
Show the next 30 plans
Showing top 50 of 100 plans.
Frequently Asked Questions
Is hydroxyurea 100 MG/ML Oral Solution [Xromi] covered by Medicare Part D?
Yes, hydroxyurea 100 MG/ML Oral Solution [Xromi] is covered by 142 Medicare Part D plans (2.8% of all Part D formularies).
What tier is hydroxyurea 100 MG/ML Oral Solution [Xromi] on Medicare Part D plans?
hydroxyurea 100 MG/ML Oral Solution [Xromi] averages Tier 3.7 across Part D plans, ranging from Tier 1 to Tier 5.
Does hydroxyurea 100 MG/ML Oral Solution [Xromi] require prior authorization?
25% of Part D formularies require prior authorization for hydroxyurea 100 MG/ML Oral Solution [Xromi]. Step therapy: 0%. Quantity limits: 0%.
How much does Medicare spend on hydroxyurea 100 MG/ML Oral Solution [Xromi]?
In 2023, total Medicare Part D spending on hydroxyurea 100 MG/ML Oral Solution [Xromi] was $17,214,624, covering 102,368 beneficiaries. The average spend per beneficiary was $168.16.
Read our methodology - how this data is sourced, computed, and verified.
Nationwide similar Part D drugs
Data-derived peers across the CMS Part D formulary extract: nearest average tier placement and nearest prior-authorization rate. Not therapeutic alternatives or same-generic strengths.
Closest average formulary tier
- 12 HR treprostinil 0.125 MG Extended Release Oral Tablet [Orenitram] T3.7
- 24 HR topiramate 50 MG Extended Release Oral Capsule T3.7
- droxidopa 200 MG Oral Capsule T3.7
- lactulose 10000 MG Powder for Oral Solution [Kristalose] T3.7
- ciprofloxacin 100 MG/ML Oral Suspension [Cipro] T3.7
- zonisamide 20 MG/ML Oral Suspension [Zonisade] T3.7
Similar prior-authorization rate
- lorazepam 0.5 MG Oral Tablet 25% PA
- insulin lispro-aabc 100 UNT/ML Injectable Solution [Lyumjev] 25% PA
- desipramine hydrochloride 10 MG Oral Tablet 25% PA
- desipramine hydrochloride 100 MG Oral Tablet 25% PA
- methotrexate 5 MG Oral Tablet [Trexall] 25% PA
- Modified 24 HR metformin hydrochloride 1000 MG Extended Release Oral Tablet 25% PA